RNS Number: 5565G Thruvision Group PLC 06 November 2025



6 November 2025

Thruvision Group plc ("Thruvision" or the "Company") **Blocklisting update**

Thruvision (AIM:THRU, "Thruvision" or the "Group"), a leading international provider of walk-through security technology, today announces an update to its blocklisting application.

Name of Company: Thruvision Group plc

Name of Scheme: Thruvision Group plc Sharesave Scheme

Balance of Ordinary 1p shares under the

Scheme at 7 May 2025:

68.251

Number of Ordinary 1p shares issued

under the Scheme during the period:

Nil

Nil

Number of Ordinary 1p shares cancelled under the scheme during the period:

Balance of Ordinary 1p shares under the

68,251

Scheme at 6 November 2025:

At 6 November 2025 the total number of Ordinary Shares in issue with voting rights is 448,559,010.

No Ordinary Shares are held in treasury.

The above figure of 448,559,010 Ordinary Shares in the Company carrying voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

Thruvision Group plc +44 (0)1235 425400

Victoria Balchin, Chief Executive Officer

Allenby Capital Limited (NOMAD & Broker) +44 (0)20 3328 5656

James Reeve / Piers Shimwell

About Thruvision (www.thruvision.com)

Thruvision is a leading developer, manufacturer and supplier of walk-through security technology. Its technology is deployed in more than 30 countries around the world by government and commercial organisationsin a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using an advanced Al-based detection algorithm. The Group's offices are near Oxford and Washington DC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BLRUPGWPGUPAGQQ